# TRDMT1 methyltransferase gene knockout attenuates STING-based cell death signaling during self-extracellular RNA-mediated response in drug-induced senescent osteosarcoma cells

**Authors:** Gabriela Betlej, Anna Deręgowska, Maciej Wnuk, Dominika Błoniarz, Tomasz Szmatoła, Katarzyna Klimczak, Jagoda Adamczyk-Grochala, Julia Świętoń, Anna Lewińska

PMC · DOI: 10.1007/s00018-025-05835-1 · 2025-08-13

## TL;DR

This study shows that knocking out the TRDMT1 gene reduces immune responses and cell death in drug-resistant osteosarcoma cells triggered by self-RNA.

## Contribution

The study reveals a novel role of TRDMT1 in modulating STING-based immune signaling in senescent osteosarcoma cells.

## Key findings

- TRDMT1 gene knockout prevents STING activation and proinflammatory responses in senescent osteosarcoma cells.
- TRDMT1 KO leads to replication stress and increased APOBEC3A/G levels when exposed to self-RNA.
- RNA D and RNA S induce immune responses and cell death in proliferating osteosarcoma cells.

## Abstract

Under stress conditions, endogenous biomolecules such as nucleic acids or proteins can be released from damaged cells and considered as damage-associated molecular patterns (DAMPs) activating innate immune system and context-dependent responses. In the present study, self-extracellular RNA was obtained from dying (RNA D) and senescent (RNA S) cellular models of osteosarcoma (OS), characterized by NGS, and tested against proliferating and non-proliferating (etoposide-indued senescent) OS cells (U-2 OS, SaOS-2, MG-63, 143B). RNA D and RNA S induced apoptosis, nitro-oxidative stress, nucleic acid sensing pathways and cytokine production, and RNA m5C methyltransferase-based responses (TRDMT1 and NSUN2) in proliferating OS cells. In drug-induced senescent OS cells, TRDMT1 gene knockout (KO) prevented STING activation, related proinflammatory response, and cell death. Furthermore, IFN-β binding RNA partners were identified, namely NSUN2, NSUN5, NSUN6, CDKN1A, MYC, and RAD51 transcripts and these interactions were compromised in TRDMT1 KO cells and upon RNA D and RNA S treatment. TRDMT1 KO also resulted in replication stress in OS cells that was potentiated by RNA D and RNA S stimulation and associated with elevated levels of APOBEC3A and APOBEC3G, members of the cytidine deaminase protein family. In conclusion, we showed that TRDMT1 KO restricted STING-based immune and cell death response to RNA D and RNA S in non-proliferating drug resistant OS cells that might have potential therapeutic implications.

The online version contains supplementary material available at 10.1007/s00018-025-05835-1.

## Linked entities

- **Genes:** TRDMT1 (tRNA aspartic acid methyltransferase 1) [NCBI Gene 1787], NSUN2 (NOP2/Sun RNA methyltransferase 2) [NCBI Gene 54888], NSUN5 (NOP2/Sun RNA methyltransferase 5) [NCBI Gene 55695], NSUN6 (NOP2/Sun RNA methyltransferase 6) [NCBI Gene 221078], CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026], MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609], RAD51 (RAD51 recombinase) [NCBI Gene 5888], APOBEC3A (apolipoprotein B mRNA editing enzyme catalytic subunit 3A) [NCBI Gene 200315], APOBEC3G (apolipoprotein B mRNA editing enzyme catalytic subunit 3G) [NCBI Gene 60489]
- **Chemicals:** etoposide (PubChem CID 36462)
- **Diseases:** osteosarcoma (MONDO:0002623)

## Full-text entities

- **Genes:** STING1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 340061] {aka ERIS, MITA, MPYS, NET23, SAVI, STING}, APOBEC3G (apolipoprotein B mRNA editing enzyme catalytic subunit 3G) [NCBI Gene 60489] {aka A3G, ARCD, ARP-9, ARP9, CEM-15, CEM15}, CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026] {aka CAP20, CDKN1, CIP1, MDA-6, P21, SDI1}, NSUN2 (NOP2/Sun RNA methyltransferase 2) [NCBI Gene 54888] {aka MISU, MRT5, SAKI, TRM4}, TRDMT1 (tRNA aspartic acid methyltransferase 1) [NCBI Gene 1787] {aka DMNT2, DNMT2, MHSAIIP, PUMET, RNMT1}, RAD51 (RAD51 recombinase) [NCBI Gene 5888] {aka BRCC5, FANCR, HRAD51, HsRad51, HsT16930, MRMV2}, IFNB1 (interferon beta 1) [NCBI Gene 3456] {aka IFB, IFF, IFN-beta, IFNB}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, APOBEC3A (apolipoprotein B mRNA editing enzyme catalytic subunit 3A) [NCBI Gene 200315] {aka A3A, ARP3, PHRBN, bK150C2.1}, NSUN6 (NOP2/Sun RNA methyltransferase 6) [NCBI Gene 221078] {aka 4933414E04Rik, ARL5B-AS1, MRT82, NOPD1}, NSUN5 (NOP2/Sun RNA methyltransferase 5) [NCBI Gene 55695] {aka NOL1, NOL1R, NSUN5A, WBSCR20, WBSCR20A, p120}
- **Diseases:** OS (MESH:D012516)
- **Chemicals:** etoposide (MESH:D005047)
- **Cell lines:** U-2 OS — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_F865), MG-63 — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_0426), SaOS-2 — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_0548), 143B — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_2270)

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12350886/full.md

---
Source: https://tomesphere.com/paper/PMC12350886